Home
About
Who we are
What we do
The rationale for AVRA
A robust vaccine pipeline
The global and national context
Expected benefits
Governance and management
Key Activities
Antigen surveillance
Vaccine platform technologies
Adjuvant development
Antigen discovery
Animal models
Vaccine immunity
Vaccine manufacturing partners
Clinical trials
Education and training
People
Partners
News and Events
Contact
Menu
New defence against dengue and emerging mosquito-borne viruses
Jan 8, 2021
Doherty Institute receives MRFF funding for COVID-19 vaccine Phase I clinical trial
Jan 3, 2021
Improving vaccination rates by dispelling mistrust and conspiracy
Dec 17, 2020
Sydney to undertake clinical studies of needle-free vaccine patch
Nov 23, 2020
University of Sydney to advance COVID-19 DNA vaccine to human trials
Sep 24, 2020
« Older Entries
Next Entries »
